Every 10-Q that Immuneering Corporation (IMRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMRX filings page.
Immuneering Corporation is a late-stage clinical oncology company advancing Deep Cyclic Inhibitor therapies, led by atebimetinib (IMM-1-104), an oral MEK inhibitor. A global Phase 3 registrational trial, MAPKeeper 301, began dosing first-line metastatic pancreatic cancer patients in June 2026, targeting about 510 patients with overall survival as the primary endpoint.
For the six months ended June 30, 2026, Immuneering reported a net loss of $30.7 million, compared with $29.5 million a year earlier, driven by $24.6 million in research and development and $9.7 million in general and administrative expenses. Net loss per share was $0.48. Cash used in operating activities was $34.9 million.
As of June 30, 2026, the company held approximately $182.7 million in cash, cash equivalents and marketable securities, total assets of $202.1 million, and stockholders’ equity of $190.7 million. Management states this liquidity is expected to fund operations, including ongoing trials, into 2029.
Immuneering Corporation is a late-stage clinical oncology company developing Deep Cyclic Inhibitors targeting the MAPK pathway, led by atebimetinib (IMM-1-104). The drug is moving into MAPKeeper 301, a global Phase 3 registrational trial in first-line metastatic pancreatic cancer, planned to enroll about 510 patients.
For the three months ended March 31, 2026, Immuneering reported a net loss of $13,460,895, modestly improved from $15,046,132 a year earlier, with basic and diluted net loss per share of $0.21 versus $0.42. Operating expenses were $15,335,034, driven mainly by $10,645,222 in research and development and $4,682,495 in general and administrative costs.
Cash and cash equivalents were $47,321,566 and marketable securities totaled $151,322,802 as of March 31, 2026, supporting management’s view that current resources can fund operations into 2029. The company remains pre-revenue, focused on advancing atebimetinib through late-stage trials and progressing its broader oncology pipeline, including envometinib (IMM-6-415).
Immuneering Corporation (IMRX) filed its Q3 2025 10-Q, highlighting a major balance sheet step-up driven by equity financings. Cash and cash equivalents were $227.6 million as of September 30, 2025, up from $36.1 million at year-end 2024, primarily from a $164.1 million underwritten offering, a $23.3 million private placement with Aventis (Sanofi), a $23.4 million August private placement including pre-funded and purchase warrants, and activity under its ATM program.
Operations remained consistent with development stage activity. Q3 2025 net loss was $15.0 million (loss per share $0.38), with R&D $10.9 million and G&A $4.5 million. For the nine months, the company reported a $44.4 million net loss. Management stated its cash is expected to fund operations for at least 12 months from issuance. The company continues advancing atebimetinib (IMM‑1‑104), including an ongoing Phase 1/2a and a planned registrational trial in first-line pancreatic cancer. Shares outstanding were 64,569,967 Class A as of November 5, 2025.
Immuneering Corporation is a clinical-stage oncology company focused on Deep Cyclic Inhibition of the MAPK pathway with lead candidate atebimetinib (IMM-1-104) in a Phase 1/2a trial. Interim data from the mGnP combination arm at the 320 mg once-daily dose show a 6‑month overall survival of 94% and 6‑month progression-free survival of 72% in the 34‑patient intent-to-treat cohort; among 36 response-evaluable patients at 240/320 mg, the interim disease control rate was 81% and overall response rate was 39%. Safety at the 320 mg dose was described as generally well tolerated with Grade ≥3 events ≥10% limited to Anemia 18% and Neutropenia 15%, and no Grade 5 events reported.
On the financial side, cash and cash equivalents were $26.36 million at June 30, 2025, down from $36.14 million at year-end; the company reported a net loss of $29.48 million for the six months and used $23.53 million in operating cash during the period. The company raised $13.7 million net from an ATM equity program in the six months. Management disclosed substantial doubt about the company’s ability to continue as a going concern for one year without additional funding and plans to pursue further financing and strategic options.